Acutaas Chemicals LtdQ1 FY23Pharmaceuticals & Biotechnology

Acutaas Chemicals Ltd

Q1 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→The company expects a 25%+ growth in specialty chemicals and 20%-22% growth in the core pharma business (Page 14).
→Volume growth, rather than price increases, will drive top-line growth as prices are currently suppressed (Page 16).
→The new Ankleshwar greenfield facility, operational by December 2023, will enable 4x volume growth compared to Unit 1 in Surat, supporting FY '24 to FY '26 growth (Pages 10, 17).
→Specialty chemical segment aims for 2.5x revenue growth over the next 2-3 years, with several new molecules to be commercialized in FY '24 (Pages 8-9).
→Electrolyte additives segment expects initial revenues from H1 FY '24, with a large market opportunity ($2-$3 billion industry) and capacity expansion planned as orders increase (Pages 4,13,17).
→Baba Fine Chemicals acquisition anticipates 3-4x growth in revenue in the near term due to new product launches and expanded global market reach (Page 13).

Category 2

→FY'24 revenue growth expected to continue strongly, driven by advanced pharmaceutical intermediates and specialty chemicals with a 2.5x revenue growth target in 2-3 years.
→EBITDA margins improving quarter-on-quarter; currently at 21.9% with sustained margin improvement expected.
→PAT margins steady with a 15.8% YoY growth reported for FY'23; further margin expansion likely as high-value contracts mature.
→Specialty chemical segment aiming for 18%-19% margins this year, up from previous levels.
→Margin expansion is a continuous process; expected 100-150 bps improvement with better volumes and operational efficiencies over FY'24 and FY'25.
→New product introductions and long-term contracts (e.g., Fermion) will drive revenue visibility and margin improvement.
→Capex for growth (including electrolyte segment) suggests scaling up operations, supporting volume and profitability growth.
→Conservative guidance on margin reductions due to new product capacity investments, but overall profitability is expected to improve as volumes grow.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Acutaas Chemicals Ltd and 1,400+ other companies.

→For the Baba deal, Ami Organics will not be raising any significant debt; instead, they will be issuing preferential shares corresponding to the INR68 crore deal value.
→There will be minimal cash involvement in the Baba deal.
→Current year capex guidance is INR200-220 crores, including the Ankleshwar brownfield project, but no mention of new fundraising for this.
→Maintenance capex is INR35 crores, with additional capex planned for solar and electrolyte capacity, to be announced later.
→No explicit mention of any other immediate or planned fundraising through debt or equity in the discussion.

→Several contracts for FY '25 and FY '26 are in line, including in UV absorbers and petrochemicals, with Letters of Intent (LOIs) already signed.
→LOIs will be disclosed once they materialize and convert into Memorandums of Understanding (MOUs) in FY '24 and '25.
→Specialized contracts including electrolyte additives show progressing orders, with 6 customers approved worldwide and plant-scale trial commercial orders received.
→Orders for VCB and FEC electrolyte products are in hand; commercialization expected this year with both domestic and international customers.
→Working capital improvements and growing order book support sustained growth.
→No specific exact current total order book value mentioned, but positive outlook on conversion of LOIs to firm orders and expected volume growth across segments.

Yes

→For FY 2024, capex outlay is expected between INR 200 crores to INR 220 crores, including the brownfield project at Ankleshwar.
→Greenfield facility capex is around INR 160-170 crores scheduled for this year.
→Maintenance capex (excluding electrolyte business) is about INR 35 crores.
→Additional capex planned for solar projects though specifics will be announced later.
→Electrolyte business capex is anticipated in the second half of FY 2024 once orders increase; exact amount to be announced.
→Total capex for the year exceeds INR 200 crores when combining greenfield and other projects.
→Capacity expansions ongoing at Unit 3 (Jaghadia) to increase specialty chemicals production by about 15-20%.
→Future capex plans depend on order inflows, especially from electrolyte and solar segments.

How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Acutaas Chemicals Ltd

Rev 2Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Acutaas Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.